WallStSmart

Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vsMedtronic PLC (MDT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 3498% more annual revenue ($37.54B vs $1.04B). MDT leads profitability with a 13.9% profit margin vs -2.7%. MDT earns a higher WallStSmart Score of 68/100 (B-).

LMRI

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 7/9Altman Z: 0.57

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LMRI.

MDTUndervalued (+9.3%)

Margin of Safety

+9.3%

Fair Value

$94.25

Current Price

$88.48

$5.77 discount

UndervaluedFair: $94.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LMRI1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$111.40B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

LMRI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$974.68M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Debt/EquityHealth
1.593/10

Elevated debt levels

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : LMRI

The strongest argument for LMRI centers on Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : LMRI

The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin. Debt-to-equity of 1.59 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

LMRI profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 38/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lumexa Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?